Overview

A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever

Status:
Active, not recruiting
Trial end date:
2025-10-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals